Sol-Gel Technologies Ltd
NASDAQ:SLGL
| Market Cap (Intraday) | 22.75M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $7.58 |
| 50-Day MA | $7.37 |
| 200-Day MA | $6.85 |
Sol-Gel Technologies Ltd Stock, NASDAQ:SLGL
Weizmann Science Park, 7 Golda Meir Street, Ness Ziona, Tel Aviv 74036
Israel
Phone: +972.8.931.3433
Number of Employees: 36
Description
Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.